Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985538 | 0.78 | KMO (0.47) | KMO | |
| SCHEMBL7070159 | 0.78 | POLB (0.30) | — | |
| Water SCHEMBL9423366 | 0.77 | KMO (0.46) | KMO | |
| SCHEMBL125608 | 0.75 | — | — | |
| SCHEMBL3808604 | 0.69 | KDM4E (0.42) | — | |
| SCHEMBL14609864 | 0.69 | BAZ2B (0.44) | — | |
| SCHEMBL508369 | 0.69 | — | — | |
| SCHEMBL29411916 | 0.69 | — | — | |
| SCHEMBL26113092 | 0.67 | POLB (0.40) | — | |
| SCHEMBL1671480 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6570015-B2 | Reacting alpha-keto ester with an isothiourea | UBE INDUSTRIES, LTD. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | UBE INDUSTRIES, LTD. (JP) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055252-A1 | Process for producing 2-substituted thiopyrimidine-4-carboxylate | DHFR, TYMS, DPYD | KMO 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.